Simcere Pharmaceutical Group Limited (HK:2096)
:2096
Total Valuation
Simcere Pharmaceutical Group Limited has a market cap or net worth of HK$25.53B. The enterprise value is HK$18.54B.
Market CapHK$25.53B
Enterprise ValueHK$18.54B
Share Statistics
Simcere Pharmaceutical Group Limited has 2,568,198,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,568,198,700
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Simcere Pharmaceutical Group Limited’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is 11.05%.
Return on Equity (ROE)0.14
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)11.05%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee1.17M
Profits Per Employee230.00K
Employee Count6,584
Asset Turnover0.52
Inventory Turnover2.41
Valuation Ratios
The current PE Ratio of Simcere Pharmaceutical Group Limited is 15.5. Simcere Pharmaceutical Group Limited’s PEG ratio is 0.23.
PE Ratio15.5
PS Ratio3.46
PB Ratio2.84
Price to Fair Value2.84
Price to FCF23.24
Price to Operating Cash Flow9.87
PEG Ratio0.23
Income Statement
In the last 12 months, Simcere Pharmaceutical Group Limited had revenue of 7.73B and earned 1.34B in profits. Earnings per share was 0.54.
Revenue7.73B
Gross Profit6.31B
Operating Income1.56B
Pretax Income1.51B
Net Income1.34B
EBITDA1.72B
Earnings Per Share (EPS)0.54
Cash Flow
In the last 12 months, operating cash flow was 2.11B and capital expenditures -343.50M, giving a free cash flow of 1.77B billion.
Operating Cash Flow2.11B
Free Cash Flow1.77B
Free Cash Flow per Share0.69
Dividends & Yields
Simcere Pharmaceutical Group Limited pays an annual dividend of HK$0.207, resulting in a dividend yield of 1.36%
Dividend Per ShareHK$0.207
Dividend Yield1.36%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.61
52-Week Price Change-11.22%
50-Day Moving Average11.25
200-Day Moving Average12.12
Relative Strength Index (RSI)34.95
Average Volume (3m)9.82M
Important Dates
Simcere Pharmaceutical Group Limited upcoming earnings date is Mar 31, 2023, TBA (Confirmed).
Last Earnings DateAug 31, 2022
Next Earnings DateMar 31, 2023
Ex-Dividend Date―
Financial Position
Simcere Pharmaceutical Group Limited as a current ratio of 2.21, with Debt / Equity ratio of 12.71%
Current Ratio2.21
Quick Ratio2.03
Debt to Market Cap0.04
Net Debt to EBITDA-1.37
Interest Coverage Ratio16.24
Taxes
In the past 12 months, Simcere Pharmaceutical Group Limited has paid 170.32M in taxes.
Income Tax170.32M
Effective Tax Rate0.11
Enterprise Valuation
Simcere Pharmaceutical Group Limited EV to EBITDA ratio is 14.20, with an EV/FCF ratio of 21.20.
EV to Sales3.16
EV to EBITDA14.20
EV to Free Cash Flow21.20
EV to Operating Cash Flow12.12
Balance Sheet
Simcere Pharmaceutical Group Limited has HK$3.62B in cash and marketable securities with HK$1.20B in debt, giving a net cash position of HK$2.42B billion.
Cash & Marketable SecuritiesHK$3.62B
Total DebtHK$1.20B
Net CashHK$2.42B
Net Cash Per ShareHK$0.94
Tangible Book Value Per ShareHK$3.15
Margins
Gross margin is 81.61%, with operating margin of 20.12%, and net profit margin of 17.38%.
Gross Margin81.61%
Operating Margin20.12%
Pretax Margin19.59%
Net Profit Margin17.38%
EBITDA Margin22.24%
EBIT Margin18.33%
Analyst Forecast
The average price target for Simcere Pharmaceutical Group Limited is HK$18.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$18.67
Price Target Upside35.39% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast16.62%
EPS Growth Forecast86.93%